Prescription Medicines
Terbin Tab.
- Product Category
- An Antifungal Agent with Reliable Fungicidal Activity
- Active Ingredients
- Terbinafine hydrochloride
- Appearance
- White-light yellow round tablet
- Reimbursement Code
- 648102110
01 / 02
1. Composition and Strength
1 tablet
- Active ingredient: Terbinafine hydrochloride (USP) ----- 140.625mg (125mg as terbinafine)
- Additives: Microcrystalline cellulose, magnesium stearate, colloidal silicon oxide, croscarmellose sodium, hypromellose 2910
2. Effectiveness
1. Adult
1) The following dermatomycoses caused by dermatophytes: tinea pedis, tinea corporis, tinea pedis (jock itch)
2) Hand and toenail mycosis
2. Pediatrics
Tinea capitis
3. Dosage and dosage
1. Adult
Terbinafine hydrochloride is administered at a dose of 125 mg twice a day or 250 mg once a day.
The administration period depending on the disease is as follows.
1) Dermatophytosis
Tinea pedis (interphalangeal type, plantar type/moccasin type): 2 to 6 weeks
Tinea corporis: 2 to 4 weeks
Tinea capitis (jock itch): 2 to 4 weeks
2) Hand and toenail mycosis
It is usually administered for 6 weeks to 3 months. If the fingernails or relatively small toes are infected, or if the patient is young, the treatment period may be shortened to 3 months or less. The treatment period for toenail infection is usually sufficient for 3 months, but in some patients it may take 6 months or longer. For patients with slow toenail growth, the treatment period may be longer.
2. Children: Administer to children over 2 years of age. Administration is not recommended for children under 2 years of age as there is no experience with administration.
Tinea capitis: 4 weeks
Tinea capitis mainly occurs in children.
To prevent recurrence of infection, treatment must be performed regularly and for an appropriate period of time.
1) Weighing less than 20 kg (under 5 years of age): 62.5 mg once, administered once a day. Because there is insufficient administration experience, the decision to administer should be made considering the benefits and risks of treatment.
2) Body weight 20 to 40 kg (5 to 12 years old): 125 mg once, administered once a day.
3) Weight exceeding 40 kg (over 12 years of age): Administer 250 mg once a day.
3. Patients with renal impairment
For patients whose creatinine clearance is less than 50 mL per minute, reduce the daily dose by 1/2.
4. Precautions for use
1. Warning
1) This drug is not recommended for patients with chronic or active liver disease. Before prescribing this drug, the presence or absence of liver disease and a history of liver disease should be confirmed. Since hepatotoxicity can occur regardless of the presence or absence of a history of liver disease, an AST/ALT test is recommended for all patients before administering this drug, and adequate observation such as regular liver function tests is performed during treatment (4-6 weeks after treatment). If liver function test values rise, this medication should be discontinued immediately. If symptoms suspected of liver function abnormalities appear while taking this drug, such as persistent nausea, decreased appetite, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, or loose stools without any particular reason, the patient should be informed to report this to the doctor immediately. If these symptoms appear, the drug should be discontinued and the patient's liver function should be tested immediately.
2) In very rare cases, there have been reports of liver failure leading to death or liver transplantation due to the use of this drug to treat hand and toenail mycosis, regardless of the presence or absence of a history of liver disease. The majority of patients presenting with liver failure had serious underlying systemic diseases, and the causal relationship with this drug was unclear. If progression of liver damage is confirmed due to administration of this drug, administration should be discontinued immediately and liver function tests should be performed regularly when administering this drug.
2. Do not administer to the following patients
1) Patients with a history of hypersensitivity to this drug or its components
2) Patients with chronic or active liver disease (A single-dose pharmacokinetic study in patients with a history of liver disease showed that the elimination rate of this drug in the body can be reduced by about 50%.)
3) Patients with blood diseases such as neutrophil reduction, pancytosis, agranulocytosis, and thrombocytopenia
4) Patients with severe renal failure
5) Nursing mothers
6) Infants under 2 years of age (no administration experience)
3. Administer with caution to the following patients.
1) The use of this drug in patients with impaired renal function (creatinine clearance < 50 ml/min or serum creatinine ≥ 300 μmol/l) has not been sufficiently studied and is not recommended.
2) Elderly (age 65 or older)
3) Infants and children weighing less than 20 kg
4) In very rare cases, serious skin reactions (e.g., Stevenson-Johnson syndrome, toxic epidermal necrolysis, eosinophilia, and rash accompanied by systemic symptoms) have been reported in patients taking this drug. If a progressive skin rash occurs, you should stop taking this medicine.
Because acceleration or aggravation of psoriasis and skin and systemic lupus erythematosus has been reported in post-marketing surveillance, this drug should be used with caution when used in patients with psoriasis or systemic lupus erythematosus.
4. Adverse reactions
The frequency of adverse reactions was classified as very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1000, <1/100), rare (≥1/10000, <1/1000), and very rare (<1/10000).
1) Liver: In rare cases, important liver disorders such as hepatobiliary system failure (primarily due to cholestasis, including severe liver failure that causes death or requires liver transplantation in very rare cases), hepatitis, cholestasis, and jaundice may occur. Liver function tests should be performed once a month for the first two months of administration, paying attention to accompanying symptoms such as rash, itchy skin, fever, nausea, vomiting, loss of appetite, and malaise. Afterwards, regular examinations are conducted and if any abnormalities appear, administration is stopped and appropriate measures are taken. Rarely, elevations of liver enzymes such as γ-GTP, AST/ALT, LDH, and ALP may occur.
2) Blood and lymphatic system: In very rare cases, neutrophil reduction, pancytopenia, agranulocytosis, and thrombocytopenia may occur. Therefore, perform regular blood tests while paying attention to accompanying symptoms such as pharyngitis, fever, lymph node swelling, purpura, and subcutaneous hemorrhage. If any abnormalities appear, stop administration and take appropriate measures. In rare cases, a decrease in white blood cells and anemia may occur.
3) Skin: Very commonly, rash, itchiness, rarely, photosensitivity reaction, very rarely, mucocutaneous ophthalmic syndrome (Stevens-Johnson syndrome), toxic epidermal necrolysis (Riel syndrome), acute systemic rash pustulosis, erythema multiforme, toxic skin rash, exfoliative dermatitis, and blistering dermatitis may occur. Observe thoroughly, and if abnormalities appear, stop administration and take appropriate measures. Psoriatic rash or worsening of psoriasis and hair loss may occur.
4) Musculoskeletal system: Very commonly, musculoskeletal reactions (arthralgia, muscle pain) may occur, and if rhabdomyolysis occurs accompanied by rapid deterioration of renal function characterized by muscle pain, weakness, elevated CPK, and elevated myoglobin in the blood and urine, administration should be stopped immediately and appropriate measures should be taken.
5) Shock: If symptoms such as a drop in blood pressure, difficulty breathing, or chest pressure appear, stop administration immediately and take appropriate measures.
6) Hypersensitivity reaction: In rare cases, urticaria, erythema, and rarely facial edema and lymphatic swelling may occur.
7) Digestive system: Very commonly, gastrointestinal symptoms (abdominal distension, decreased appetite, indigestion, nausea, mild abdominal pain, diarrhea), less commonly, stomach discomfort, thirst, and rarely, vomiting and gingivitis may occur.
8) Mental system: commonly depression, uncommon anxiety
9) Nervous system: Headache very commonly, dysgeusia including loss of taste commonly, dizziness, uncommon drowsiness, paresthesia and hypoesthesia, rarely decreased attention, and insomnia may occur.
10) Urinary system: Rarely, BUN may increase, and in rare cases, frequent urination may occur.
11) Eyes: Visual impairment is common, and changes in the lens and retina have been reported in clinical trials, but the clinical significance is unclear.
12) Ears: Tinnitus may occur in rare cases.
13) Immune system: In very rare cases, anaphylactoid reactions (including angioedema, superficial and systemic lupus erythematosus) may occur.
14) Others: Rarely, elevated blood total cholesterol, elevated triglyceride levels, malaise, rarely tongue discoloration, palpitations, edema, menstrual abnormalities, paralysis, and systemic disorders, uncommonly fever, commonly fatigue, and uncommonly weight loss may occur as a result of examination.
15) Other adverse reactions reported voluntarily after marketing (frequency unknown)
The adverse drug reactions that appeared in voluntary post-marketing reports are as follows. Since these adverse reactions were reported voluntarily in a population group of unclear size, it is difficult to reliably assess their frequency.
Immune system: Anaphylactic reaction, serum sickness-like reaction
Eyes: Blurred vision, decreased vision
Ear and labyrinth abnormalities: hearing loss, deafness, tinnitus
Vascular disorders: vasculitis
Nervous system: Anosmia, hyposmia, including permanent loss of smell
Skin and subcutaneous tissue system: Drug rash accompanied by eosinophilia and systemic symptoms
Gastrointestinal system: pancreatitis
Musculoskeletal and connective tissue: rhabdomyolysis
General and administration site: Influenza-like illness
Test: Increased blood creatine phosphatase
5. General precautions
1) This drug should be administered only for mycoses that cannot be treated locally.
2) Data on the effects of this drug on the ability to drive and operate machinery have not yet been established. Patients who experience dizziness as an adverse reaction should avoid driving and operating machinery.
6. Interaction
1) The plasma clearance of this drug may be accelerated by drugs that induce metabolism and may be inhibited by drugs that inhibit CYP450. The plasma clearance of this drug was increased by 100% by metabolic accelerators such as rifampicin and decreased by 33% by CYP450 inhibitors such as cimetidine. Therefore, when coadministered with these drugs, the dose of this drug must be adjusted.
2) In vitro tests and tests on healthy volunteers showed that this drug had a negligible possibility of inhibiting or causing the clearance of most drugs (e.g. terfenadine, triazolam, tolbutamide, oral contraceptives, etc.) that are metabolized via other CYP450s rather than via CYP450 2D6.
3) Patients who are taking this medicine together with drugs that are mainly metabolized by CYP450 2D6 enzymes, such as tricyclic antidepressants (TCAs), beta blockers, selective serotonin reuptake inhibitors (SSRIs), Class 1A, 1B and 1C arrhythmia drugs, and MAO type B inhibitors, should be carefully observed, and reduction of these concomitant drugs may be necessary. In particular, if the therapeutic range of the concomitant drugs is narrow, be sure to observe carefully.
4) This drug reduced the plasma clearance of intravenously administered caffeine by 21%.
5) This drug reduced the plasma clearance of desipramine by 82% and increased the AUC by 5-fold.
6) This drug increased the plasma clearance of cyclosporine by 15%.
7) In in vivo studies, this drug did not affect the clearance of antipyrine or digoxin.
8) Exercise caution as menstrual abnormalities have been reported in patients taking this drug together with oral contraceptives and progesterone-estrogen combination preparations.
9) Fluconazole increased the Cmax and AUC of this drug by 52% and 69%, respectively, because it inhibits both CYP2C9 and CYP3A4 enzymes. A similar increase in exposure may occur when ketoconazole is coadministered with other drugs that inhibit CYP2C9 and CYP3A4, such as amiodarone.
10) This drug does not affect the pharmacokinetics of fluconazole. Additionally, there are no clinically significant interactions between cotrimoxazole (trimethoprim and sulfamethoxazole), zidovudine, or theophylline, which can be administered concomitantly with this drug.
11) In a study of healthy subjects who were extensive metabolizers of dextrometholphan (an antitussive drug, CYP2D6 probe substrate), this drug increased the urinary dextrometholphan/dextolphan metabolism ratio by an average of 16-97 times. Therefore, this drug can convert an extensive metabolizer into a poor metabolizer state.
7. Administration to women of childbearing potential, pregnant women, and lactating women
1) Menstrual abnormalities were reported in patients taking this drug and oral contraceptives together, and the incidence rate was within the range seen in patients taking oral contraceptives alone. There are no data available to make specific recommendations for women of childbearing age.
2) Although no adverse reactions were observed in fetal toxicity tests on animals, the safety of administration during pregnancy has not been established, so it should be administered to pregnant women or women who may be pregnant only when the therapeutic benefits are judged to outweigh the risks.
3) Since this drug passes into breast milk, nursing mothers receiving this drug should stop breastfeeding.
4) There is no relevant data on human administration experience, but no adverse reactions to fertility or reproductive function were observed in rat fertility tests.
8. Administration to children
Since there is no experience in administering to infants under 2 years of age, administration is not recommended. Additionally, because there is a lack of experience in administering to infants and children weighing less than 20 kg, administration should be decided by considering benefits and losses.
9. Administration to elderly people
This drug is mainly metabolized in the liver and excreted in bile or urine. Elderly people generally have reduced liver and kidney function, so there is a risk that high blood levels will persist and adverse reactions are likely to occur, so administer with caution while observing the patient's condition.
10. Treatment in case of overdose
A few cases of overdose (up to 5 g) have been reported, with symptoms including headache, nausea, epigastric pain, and dizziness. Treatment primarily involves removal of the drug by administering activated charcoal, followed by symptomatic treatment according to the symptoms.
11. Storage and handling precautions
1) Store this medicine in a place where children cannot see it and out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
3) Store this medicine at room temperature, avoiding sunlight.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle, 100 tablets/bottle
7. Expiration date
36 months from date of manufacture
1 tablet
- Active ingredient: Terbinafine hydrochloride (USP) ----- 140.625mg (125mg as terbinafine)
- Additives: Microcrystalline cellulose, magnesium stearate, colloidal silicon oxide, croscarmellose sodium, hypromellose 2910
2. Effectiveness
1. Adult
1) The following dermatomycoses caused by dermatophytes: tinea pedis, tinea corporis, tinea pedis (jock itch)
2) Hand and toenail mycosis
2. Pediatrics
Tinea capitis
3. Dosage and dosage
1. Adult
Terbinafine hydrochloride is administered at a dose of 125 mg twice a day or 250 mg once a day.
The administration period depending on the disease is as follows.
1) Dermatophytosis
Tinea pedis (interphalangeal type, plantar type/moccasin type): 2 to 6 weeks
Tinea corporis: 2 to 4 weeks
Tinea capitis (jock itch): 2 to 4 weeks
2) Hand and toenail mycosis
It is usually administered for 6 weeks to 3 months. If the fingernails or relatively small toes are infected, or if the patient is young, the treatment period may be shortened to 3 months or less. The treatment period for toenail infection is usually sufficient for 3 months, but in some patients it may take 6 months or longer. For patients with slow toenail growth, the treatment period may be longer.
2. Children: Administer to children over 2 years of age. Administration is not recommended for children under 2 years of age as there is no experience with administration.
Tinea capitis: 4 weeks
Tinea capitis mainly occurs in children.
To prevent recurrence of infection, treatment must be performed regularly and for an appropriate period of time.
1) Weighing less than 20 kg (under 5 years of age): 62.5 mg once, administered once a day. Because there is insufficient administration experience, the decision to administer should be made considering the benefits and risks of treatment.
2) Body weight 20 to 40 kg (5 to 12 years old): 125 mg once, administered once a day.
3) Weight exceeding 40 kg (over 12 years of age): Administer 250 mg once a day.
3. Patients with renal impairment
For patients whose creatinine clearance is less than 50 mL per minute, reduce the daily dose by 1/2.
4. Precautions for use
1. Warning
1) This drug is not recommended for patients with chronic or active liver disease. Before prescribing this drug, the presence or absence of liver disease and a history of liver disease should be confirmed. Since hepatotoxicity can occur regardless of the presence or absence of a history of liver disease, an AST/ALT test is recommended for all patients before administering this drug, and adequate observation such as regular liver function tests is performed during treatment (4-6 weeks after treatment). If liver function test values rise, this medication should be discontinued immediately. If symptoms suspected of liver function abnormalities appear while taking this drug, such as persistent nausea, decreased appetite, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, or loose stools without any particular reason, the patient should be informed to report this to the doctor immediately. If these symptoms appear, the drug should be discontinued and the patient's liver function should be tested immediately.
2) In very rare cases, there have been reports of liver failure leading to death or liver transplantation due to the use of this drug to treat hand and toenail mycosis, regardless of the presence or absence of a history of liver disease. The majority of patients presenting with liver failure had serious underlying systemic diseases, and the causal relationship with this drug was unclear. If progression of liver damage is confirmed due to administration of this drug, administration should be discontinued immediately and liver function tests should be performed regularly when administering this drug.
2. Do not administer to the following patients
1) Patients with a history of hypersensitivity to this drug or its components
2) Patients with chronic or active liver disease (A single-dose pharmacokinetic study in patients with a history of liver disease showed that the elimination rate of this drug in the body can be reduced by about 50%.)
3) Patients with blood diseases such as neutrophil reduction, pancytosis, agranulocytosis, and thrombocytopenia
4) Patients with severe renal failure
5) Nursing mothers
6) Infants under 2 years of age (no administration experience)
3. Administer with caution to the following patients.
1) The use of this drug in patients with impaired renal function (creatinine clearance < 50 ml/min or serum creatinine ≥ 300 μmol/l) has not been sufficiently studied and is not recommended.
2) Elderly (age 65 or older)
3) Infants and children weighing less than 20 kg
4) In very rare cases, serious skin reactions (e.g., Stevenson-Johnson syndrome, toxic epidermal necrolysis, eosinophilia, and rash accompanied by systemic symptoms) have been reported in patients taking this drug. If a progressive skin rash occurs, you should stop taking this medicine.
Because acceleration or aggravation of psoriasis and skin and systemic lupus erythematosus has been reported in post-marketing surveillance, this drug should be used with caution when used in patients with psoriasis or systemic lupus erythematosus.
4. Adverse reactions
The frequency of adverse reactions was classified as very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1000, <1/100), rare (≥1/10000, <1/1000), and very rare (<1/10000).
1) Liver: In rare cases, important liver disorders such as hepatobiliary system failure (primarily due to cholestasis, including severe liver failure that causes death or requires liver transplantation in very rare cases), hepatitis, cholestasis, and jaundice may occur. Liver function tests should be performed once a month for the first two months of administration, paying attention to accompanying symptoms such as rash, itchy skin, fever, nausea, vomiting, loss of appetite, and malaise. Afterwards, regular examinations are conducted and if any abnormalities appear, administration is stopped and appropriate measures are taken. Rarely, elevations of liver enzymes such as γ-GTP, AST/ALT, LDH, and ALP may occur.
2) Blood and lymphatic system: In very rare cases, neutrophil reduction, pancytopenia, agranulocytosis, and thrombocytopenia may occur. Therefore, perform regular blood tests while paying attention to accompanying symptoms such as pharyngitis, fever, lymph node swelling, purpura, and subcutaneous hemorrhage. If any abnormalities appear, stop administration and take appropriate measures. In rare cases, a decrease in white blood cells and anemia may occur.
3) Skin: Very commonly, rash, itchiness, rarely, photosensitivity reaction, very rarely, mucocutaneous ophthalmic syndrome (Stevens-Johnson syndrome), toxic epidermal necrolysis (Riel syndrome), acute systemic rash pustulosis, erythema multiforme, toxic skin rash, exfoliative dermatitis, and blistering dermatitis may occur. Observe thoroughly, and if abnormalities appear, stop administration and take appropriate measures. Psoriatic rash or worsening of psoriasis and hair loss may occur.
4) Musculoskeletal system: Very commonly, musculoskeletal reactions (arthralgia, muscle pain) may occur, and if rhabdomyolysis occurs accompanied by rapid deterioration of renal function characterized by muscle pain, weakness, elevated CPK, and elevated myoglobin in the blood and urine, administration should be stopped immediately and appropriate measures should be taken.
5) Shock: If symptoms such as a drop in blood pressure, difficulty breathing, or chest pressure appear, stop administration immediately and take appropriate measures.
6) Hypersensitivity reaction: In rare cases, urticaria, erythema, and rarely facial edema and lymphatic swelling may occur.
7) Digestive system: Very commonly, gastrointestinal symptoms (abdominal distension, decreased appetite, indigestion, nausea, mild abdominal pain, diarrhea), less commonly, stomach discomfort, thirst, and rarely, vomiting and gingivitis may occur.
8) Mental system: commonly depression, uncommon anxiety
9) Nervous system: Headache very commonly, dysgeusia including loss of taste commonly, dizziness, uncommon drowsiness, paresthesia and hypoesthesia, rarely decreased attention, and insomnia may occur.
10) Urinary system: Rarely, BUN may increase, and in rare cases, frequent urination may occur.
11) Eyes: Visual impairment is common, and changes in the lens and retina have been reported in clinical trials, but the clinical significance is unclear.
12) Ears: Tinnitus may occur in rare cases.
13) Immune system: In very rare cases, anaphylactoid reactions (including angioedema, superficial and systemic lupus erythematosus) may occur.
14) Others: Rarely, elevated blood total cholesterol, elevated triglyceride levels, malaise, rarely tongue discoloration, palpitations, edema, menstrual abnormalities, paralysis, and systemic disorders, uncommonly fever, commonly fatigue, and uncommonly weight loss may occur as a result of examination.
15) Other adverse reactions reported voluntarily after marketing (frequency unknown)
The adverse drug reactions that appeared in voluntary post-marketing reports are as follows. Since these adverse reactions were reported voluntarily in a population group of unclear size, it is difficult to reliably assess their frequency.
Immune system: Anaphylactic reaction, serum sickness-like reaction
Eyes: Blurred vision, decreased vision
Ear and labyrinth abnormalities: hearing loss, deafness, tinnitus
Vascular disorders: vasculitis
Nervous system: Anosmia, hyposmia, including permanent loss of smell
Skin and subcutaneous tissue system: Drug rash accompanied by eosinophilia and systemic symptoms
Gastrointestinal system: pancreatitis
Musculoskeletal and connective tissue: rhabdomyolysis
General and administration site: Influenza-like illness
Test: Increased blood creatine phosphatase
5. General precautions
1) This drug should be administered only for mycoses that cannot be treated locally.
2) Data on the effects of this drug on the ability to drive and operate machinery have not yet been established. Patients who experience dizziness as an adverse reaction should avoid driving and operating machinery.
6. Interaction
1) The plasma clearance of this drug may be accelerated by drugs that induce metabolism and may be inhibited by drugs that inhibit CYP450. The plasma clearance of this drug was increased by 100% by metabolic accelerators such as rifampicin and decreased by 33% by CYP450 inhibitors such as cimetidine. Therefore, when coadministered with these drugs, the dose of this drug must be adjusted.
2) In vitro tests and tests on healthy volunteers showed that this drug had a negligible possibility of inhibiting or causing the clearance of most drugs (e.g. terfenadine, triazolam, tolbutamide, oral contraceptives, etc.) that are metabolized via other CYP450s rather than via CYP450 2D6.
3) Patients who are taking this medicine together with drugs that are mainly metabolized by CYP450 2D6 enzymes, such as tricyclic antidepressants (TCAs), beta blockers, selective serotonin reuptake inhibitors (SSRIs), Class 1A, 1B and 1C arrhythmia drugs, and MAO type B inhibitors, should be carefully observed, and reduction of these concomitant drugs may be necessary. In particular, if the therapeutic range of the concomitant drugs is narrow, be sure to observe carefully.
4) This drug reduced the plasma clearance of intravenously administered caffeine by 21%.
5) This drug reduced the plasma clearance of desipramine by 82% and increased the AUC by 5-fold.
6) This drug increased the plasma clearance of cyclosporine by 15%.
7) In in vivo studies, this drug did not affect the clearance of antipyrine or digoxin.
8) Exercise caution as menstrual abnormalities have been reported in patients taking this drug together with oral contraceptives and progesterone-estrogen combination preparations.
9) Fluconazole increased the Cmax and AUC of this drug by 52% and 69%, respectively, because it inhibits both CYP2C9 and CYP3A4 enzymes. A similar increase in exposure may occur when ketoconazole is coadministered with other drugs that inhibit CYP2C9 and CYP3A4, such as amiodarone.
10) This drug does not affect the pharmacokinetics of fluconazole. Additionally, there are no clinically significant interactions between cotrimoxazole (trimethoprim and sulfamethoxazole), zidovudine, or theophylline, which can be administered concomitantly with this drug.
11) In a study of healthy subjects who were extensive metabolizers of dextrometholphan (an antitussive drug, CYP2D6 probe substrate), this drug increased the urinary dextrometholphan/dextolphan metabolism ratio by an average of 16-97 times. Therefore, this drug can convert an extensive metabolizer into a poor metabolizer state.
7. Administration to women of childbearing potential, pregnant women, and lactating women
1) Menstrual abnormalities were reported in patients taking this drug and oral contraceptives together, and the incidence rate was within the range seen in patients taking oral contraceptives alone. There are no data available to make specific recommendations for women of childbearing age.
2) Although no adverse reactions were observed in fetal toxicity tests on animals, the safety of administration during pregnancy has not been established, so it should be administered to pregnant women or women who may be pregnant only when the therapeutic benefits are judged to outweigh the risks.
3) Since this drug passes into breast milk, nursing mothers receiving this drug should stop breastfeeding.
4) There is no relevant data on human administration experience, but no adverse reactions to fertility or reproductive function were observed in rat fertility tests.
8. Administration to children
Since there is no experience in administering to infants under 2 years of age, administration is not recommended. Additionally, because there is a lack of experience in administering to infants and children weighing less than 20 kg, administration should be decided by considering benefits and losses.
9. Administration to elderly people
This drug is mainly metabolized in the liver and excreted in bile or urine. Elderly people generally have reduced liver and kidney function, so there is a risk that high blood levels will persist and adverse reactions are likely to occur, so administer with caution while observing the patient's condition.
10. Treatment in case of overdose
A few cases of overdose (up to 5 g) have been reported, with symptoms including headache, nausea, epigastric pain, and dizziness. Treatment primarily involves removal of the drug by administering activated charcoal, followed by symptomatic treatment according to the symptoms.
11. Storage and handling precautions
1) Store this medicine in a place where children cannot see it and out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
3) Store this medicine at room temperature, avoiding sunlight.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle, 100 tablets/bottle
7. Expiration date
36 months from date of manufacture
Product Updates
Total 7items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 7 | Terbin Tab. | Turbine well (precautions for use) | 2014.08.19 | HWPTerbinafine hydrochloride single drug (tablet)_Unification adjustment (draft).hwp |
| 6 | Terbin Tab. | Turbine well (precautions for use) | 2012.06.08 | HWPPrecautions for using turbine wells.hwp |
| 5 | Terbin Tab. | Turbine well (precautions for use) | 2012.02.03 | HWPPrecautions for using turbine wells.hwp |
| 4 | Terbin Tab. | Turbine well (precautions for use) | 2010.09.13 | HWPTurbine tablet (precautions for use).hwp |
| 3 | Terbin Tab. | Turbine Tablet (efficacy, dosage, usage precautions... | 2007.07.23 | HWP9-3. Turbine Jeong (2007.07.23).hwp |
| 2 | Terbin Tab. | Turbine Tablet (efficacy, dosage, usage precautions... | 2008.01.02 | HWP9-2. Turbine Jeong (2008.01.02).hwp |
| 1 | Terbin Tab. | Turbine well (precautions for use) | 2008.03.18 | HWP9-1. Turbine tablet (precautions for use) (2008.03.18).hwp |